


Fighting Future Pandemics:

A Novel Approach to In Silico Drug Discovery for Global Health Priority Pathogen Nipah Henipavirus (NiV)

Lim Wan Qin

INTRODUCTION

1) A Deadly Paramyxovirus



2) The Long, Costly Drug Discovery Process

For a single drug: 12-15 years >USD 2.5 billion 90% failure rate

3) Previous Approach to Virtual Screening for NiV: Molecular Dynamics

- Require tedious preparation processes of chemical environment and proteins for accurate simulations

4) Current Drug-Target-Affinity (DTI) Models


- Encode protein residues
- Neglect atomic information

RESULTS


Binding Affinities of 7 Predicted Drugs with NiV-G and F Proteins

Ligand MMV ID	689000	674056	673982	1782412	687800	676461	1542798
NiV-G	-8.4	-8.7	-8.0	-7.4	-8.2	-7.9	-7.8
NiV-F	-10.6	-10.1	-9.7	-9.2	-9.1	-8.4	-8.2

Docked Poses of top 2 multi-target inhibitors



40 x 40 grid with highest weight values in NiV proteins' complexes with respective top 3 inhibitors





METHODOLOGY

- Curate and train a novel deep learning Graph Neural Network (GNN) model that:

- Incorporates protein atomic information
- Predicts inhibitory potential of a drug within seconds
 - Much faster than molecular simulations

DeepGraphDTI




Graph Features

Node features	Atomic number, degree, formal charge, hybridization, aromaticity, radical electrons, number of Hs, in ring, chirality
Edge features	Bond type (Aromatic, DativeL, DativeR, Dative, DativeOne, Hydrogen, Ionic, ThreeCenter, 0, 1.0, 1.5, 2.0, 2.5 3.0, 3.5 4.0, 4.5, 5.0, 5.5, 6.0), in ring
Edge Index	Graph connectivity in coordinate form (adjacency matrix)
Label	$pKi = -\log \frac{Ki}{10^6}$ where Ki is the inhibition constant (concentration of drug required to produce half maximum inhibition)

Best Model Parameters

Parameter	Value/Type
Model Layers	4
GNN Type(s)	Layer 1: GATv2Conv Layers 2-4: TransformerConv
Attention heads	3
Optimizer	Stochastic Gradient Descent
Learning Rate	0.001
Activation Function	Scaled Exponential Linear Unit (SELU)
Graph Pooling Type(s)	Concatenation of Global Max Pooling and Global Mean Pooling
Loss Function	Mean Squared Error
Batch size	16
Dense Neurons	256



DeepGraphDTI Final Algorithm

Forward Propagation:

Input: node features x ; edge features e ; edge in dex; batch index β ; trainable parameters W ; attention coefficient α ; hidden size of each attention head d ; global representation g ; linear transformation L ; batch normalisation BN; number of layers l
Output: final representation x


```
1: procedure forward
2:   for  $l = 1$  to  $l$  do
3:      $x_i \leftarrow a_{ij} W_i x_i + \sum_{j \in N(i)} a_{ij} W_j x_j$ 
4:     where  $a_{ij} = \frac{\exp(aTLeakyReLU(W_{ij} x_i + W_{ij} x_j + W_{ij} e_{ij}))}{\sum_{k \in N(i)} \exp(aTLeakyReLU(W_{ik} x_i + W_{ik} x_k + W_{ik} e_{ik}))}$ 
5:   for  $l = 2$  to  $4$  do
6:      $x_i \leftarrow W_{d,i} x_i + \sum_{j \in N(i)} a_{ij} (W_{d,j} x_j + W_{d,j} e_{ij})$ 
7:     where  $a_{ij} = \frac{\exp(aTLeakyReLU(W_{d,i} x_i + W_{d,i} x_j + W_{d,i} e_{ij}))}{\sum_{k \in N(i)} \exp(aTLeakyReLU(W_{d,i} x_i + W_{d,i} x_k + W_{d,i} e_{ik}))}$ 
8:      $x_i \leftarrow SELU(L_{d,i}(x_i))$ 
9:   end for
10:   $x_i \leftarrow \sum_{j=1}^d \alpha_j x_j$ 
11:   $x_i \leftarrow SELU(L_{d,i}(x_i))$ 
12:   $x_i \leftarrow SELU(L_{d,i}(x_i))$ 
13:   $x_i \leftarrow L_{d,i}(x_i)$ 
14:  return  $x_i$ 
```

Performance Results

Metrics

t : ground-truth value; p : predicted value
Root-Mean-Squared-Error: $RMSE(t, p) = \sqrt{\frac{1}{n} \sum_{i=1}^n (t_i - p_i)^2}$
Pearson Correlation: $PC(t, p) = \frac{n \sum t_i p_i - \sum t_i \sum p_i}{\sqrt{(n \sum t_i^2 - (\sum t_i)^2)(n \sum p_i^2 - (\sum p_i)^2)}}$

Method	RMSE↓	PC↑
DeepAffinity	0.840	0.840
DeepDTA	0.824	0.832
DeepCDA	0.808	0.844
BACPI	0.800	0.860
SSM-DTA	0.792	0.863
DeepGraphDTI	0.742	0.886



- Molecular docking on 15 drug ligands giving highest pKi with NiV-F and G predicted by DeepGraphDTI $\Rightarrow$ 7 potential inhibitors identified

CONCLUSION

- This study suggests the inhibitory potential of 7 drugs against NiV
- DeepGraphDTI, a novel DTA model which incorporates protein atomic information, outperformed competing DTI models, suggesting the value of incorporating protein atomic information in determining ligand-protein reaction outcomes, especially when focusing on localised interactions as in DTA tasks

FUTURE WORKS

- To confirm the pharmacological activity of the 7 potential inhibitors in vitro and in vivo
- To powerfully harness DeepGraphDTI for future drug discovery tasks